Ran Kornowski, Maayan Konigstein, Michael Jonas, Abid Assali, Hana Vaknin-Assa, Amit Segev, Haim Danenberg, Majdi Halabi, Ariel Roguin, Arthur Kerner, Eli Lev, Grigoris V Karamasis, Thomas W Johnson, Richard Anderson, Jonathan Blaxill, Sachin Jadhav, Stephen Hoole, Guy Witberg, Melek Ozgu Issever, Ori Ben-Yehuda, Andreas Baumbach
BACKGROUND: Patients treated with percutaneous coronary intervention are often considered to be at a high bleeding risk (HBR). Drug-eluting stents have been shown to be superior to bare-metal stents in patients with HBR, even when patients were given abbreviated periods of dual antiplatelet therapy (DAPT). Short DAPT has not been evaluated with the EluNIR ridaforolimus-eluting stent. The aim of this study was to evaluate the safety and efficacy of a shortened period of DAPT following implantation of the ridaforolimus-eluting stent in patients with HBR...
January 12, 2024: Journal of the American Heart Association